Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Zimmer Biomet Holdings pays $30 million to resolve new FCPA charges

Medical device maker Zimmer Biomet Holdings Inc. agreed Thursday to pay $30.5 million to resolve DOJ and SEC investigations into the company’s “repeat” violations of the Foreign Corrupt Practices Act.

Under a deferred prosecution agreement (pdf) with the DOJ, Zimmer Biomet will pay a criminal fine of $17.46 million and retain an independent compliance monitor for three years.… Continue Reading

DOJ: Biomet breached DPA

The DOJ said in a court filing this month that Biomet breached a 2012 deferred prosecution agreement “based on conduct in Brazil and Mexico.”

A status report filed in federal court in Washington, D.C.… Continue Reading

FCPA enforcement report for Q1 2015

During the first calendar quarter, there were two corporate FCPA enforcement actions — both through SEC administrative orders — and one individual resolution.

(Last year in Q1 there were two corporate enforcement actions and two individual Siemens-related actions).… Continue Reading

U.S., China enforcement crossfire creates new risks

At the beginning of this year, China’s president Xi Jinping promised to fight both “tigers” and “flies” — high-ranking and low-ranking corrupt officials — in his crackdown on corruption. Since then, the anti-graft campaign has led to the conviction of Bo Xilai and to the front-page investigations of foreign companies in the pharmaceutical and oil and gas sectors, among others.… Continue Reading

Double declination for Zimmer

Following a five-year investigation into the overseas marketing and sales practices of medical device makers, the DOJ and SEC won’t bring any FCPA enforcement against one of the targeted companies, Zimmer Holdings Inc.… Continue Reading

Zimmer’s latest FCPA disclosure (November 2012)

Medical device maker Zimmer Holdings, Inc. said in an SEC filing yesterday that it can’t predict the outcome of DOJ and SEC investigations into its overseas sales practices.

The enforcement agencies opened their investigations in 2007.… Continue Reading